K M Yee1, A D Struthers. 1. University Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee.
Abstract
AIMS: To assess the role of direct ATI receptor antagonism in baroreceptor modulation in man, and to perform a direct comparison of Ang II blockade at the receptor level with that of ACE inhibition. METHODS:Ten healthy male volunteers [mean age (s.d.) 23 (6.9)] pretreated withfrusemide therapy (40 mg day(-1) for 3 days prior to each visit) were studied on 3 separate days, 10 days apart, in a placebo-controlled, randomized, double-blind, cross-over fashion. On each study day, subjects were randomly given either a single-dose of enalapril 20 mg, losartan 50 mg or placebo. Baroreceptor function was assessed by measuring changes in blood pressure (BP), pulse interval (RR Int) and heart rate (HR) in response to incremental doses of intravenous phenylephrine infusions (0.2-3.6 microg kg(-1) min(-1)). RESULTS: In response to phenylephrine, no significant differences in BP responses were observed with any of the study medications but reflex heart rate responses were significantly increased with both enalapril and losartan compared with placebo (P<0.05). The (RR/AsBP ratio, taken as a measure of baroreceptor sensitivity (BRS) was significantly increased with enalapril 112.2+4.6 ms mmHg (mean+s.d.)] and losartan [11.9+3.6msmmHg(-1)] compared with placebo [9.2+4.5 ms mmHg(-1)]; i.e. enalapril and losartan increased the (RR/(delta sBP ratio by 3.0 ms mmHg(-1) (95%CI 0.5, 5.6; P<0.05) and 2.8 ms mmHg(-1) (95%CI 0.6, 5.0; P< 0.038), respectively. There were however, no significant differences between losartan and enalapril [mean difference 0.25 (95%CI - 1.6, 2.1)]. CONCLUSIONS: The present study confirms observations from animal models that blocking endogenous angiotensin II in man improves baroreceptor function. Both strategies, ATI receptor antagonism and ACE inhibition appear to be equally effective in restoring baroreceptor function in salt-depleted normotensive subjects.
RCT Entities:
AIMS: To assess the role of direct ATI receptor antagonism in baroreceptor modulation in man, and to perform a direct comparison of Ang II blockade at the receptor level with that of ACE inhibition. METHODS: Ten healthy male volunteers [mean age (s.d.) 23 (6.9)] pretreated with frusemide therapy (40 mg day(-1) for 3 days prior to each visit) were studied on 3 separate days, 10 days apart, in a placebo-controlled, randomized, double-blind, cross-over fashion. On each study day, subjects were randomly given either a single-dose of enalapril 20 mg, losartan 50 mg or placebo. Baroreceptor function was assessed by measuring changes in blood pressure (BP), pulse interval (RR Int) and heart rate (HR) in response to incremental doses of intravenous phenylephrine infusions (0.2-3.6 microg kg(-1) min(-1)). RESULTS: In response to phenylephrine, no significant differences in BP responses were observed with any of the study medications but reflex heart rate responses were significantly increased with both enalapril and losartan compared with placebo (P<0.05). The (RR/AsBP ratio, taken as a measure of baroreceptor sensitivity (BRS) was significantly increased with enalapril 112.2+4.6 ms mmHg (mean+s.d.)] and losartan [11.9+3.6msmmHg(-1)] compared with placebo [9.2+4.5 ms mmHg(-1)]; i.e. enalapril and losartan increased the (RR/(delta sBP ratio by 3.0 ms mmHg(-1) (95%CI 0.5, 5.6; P<0.05) and 2.8 ms mmHg(-1) (95%CI 0.6, 5.0; P< 0.038), respectively. There were however, no significant differences between losartan and enalapril [mean difference 0.25 (95%CI - 1.6, 2.1)]. CONCLUSIONS: The present study confirms observations from animal models that blocking endogenous angiotensin II in man improves baroreceptor function. Both strategies, ATI receptor antagonism and ACE inhibition appear to be equally effective in restoring baroreceptor function in salt-depleted normotensive subjects.
Authors: D B Brunner; G Desponds; J Biollaz; I Keller; F Ferber; H Gavras; H R Brunner; J L Schelling Journal: Br J Clin Pharmacol Date: 1981-05 Impact factor: 4.335
Authors: A H Gradman; K E Arcuri; A I Goldberg; L S Ikeda; E B Nelson; D B Snavely; C S Sweet Journal: Hypertension Date: 1995-06 Impact factor: 10.190
Authors: Aristides Polyzos; Nicholas Tsavaris; Christos Kosmas; Helen Gogas; George Koutinos; Nicholas I Nikiteas; Evangelos Felekouras; Gregory Kouraklis; Othon Papadopoulos; Antonios Papachristodoulou; Demetrios Stamatiadis; Michael Safioleas; George Nikou Journal: Clin Drug Investig Date: 2004 Impact factor: 2.859
Authors: Deepa Sumukadas; Rosemary Price; Marion E T McMurdo; Petra Rauchhaus; Allan Struthers; Stephen McSwiggan; Graham Arnold; Rami Abboud; Miles Witham Journal: Age Ageing Date: 2018-01-01 Impact factor: 10.668